Skip to main content
SpringerLink
Log in
Book cover

Chronic Lymphocytic Leukemia pp 147–164Cite as

Genotypic Prognostic Markers

  • Chapter

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 294))

Abstract

In chronic lymphocytic leukemia (CLL), genetic analyses by fluorescence in situ hybridization (FISH) and DNA sequencing have greatly improved our understanding of pathogenic events and prognostic markers. On the one hand, there are genomic aberrations, which are detected in over 80% of CLL cases, and genes potentially involved in pathogenesis were identified with ATM in a subset of cases with 11q deletion and p53 in cases with 17p13 deletion. Genetic subgroups with distinct clinical features have been identified, such as the 11q deletion that is associated with marked lymphadenopathy and rapid disease progression, while the 17p deletion predicts treatment failure with alkylating agents as well as fludarabine and short survival times. On the other hand, there is the mutation status of the VH genes that allows the separation of patients into long (mutated VH) or short (unmutated VH) survival times. V-gene usage, VDJ structure, and gene expression differences in the two subgroups allowinsights into differential pathogenic mechanisms and provide further prognostic information (V3-21 usage, ZAP-70 expression). Most importantly, the VH mutation status and genomic abnormalities have been shown to be of independent prognostic value inmultivariate analysis, appear to allow outcome predication irrespective of the clinical stage, and may therefore allow a risk assessment of individual patients early in the course of the disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bergmann M, Eichhorst B, Busch R, Hallek M (2003) Elevated thymidine kinase and short lymphocyte doubling time in combination with unfavourable cytogenetics or unmutated IgVH status are strong predictors for high individual risk for rapid disease progression in patients with B-CLL in Binet stage A: an interim report from the CLL1 protocol of the German CLL Study Group (GCLLSG). Blood 102:Abstr 2464

    Google Scholar 

  • Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jaquillat C, Boivin P, Lesty C, Duaalt MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198

    PubMed  CAS  Google Scholar 

  • Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Profitt JH, Heerema NA (2003) Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63:36–38

    PubMed  CAS  Google Scholar 

  • Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez A, Campo E, Montserrat E (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764–1775

    Article  PubMed  CAS  Google Scholar 

  • Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840

    PubMed  CAS  Google Scholar 

  • Dewald GW, Brockman SR, Paternoster SF, Bone ND, O’Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE (2003) Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 121:287–295

    Article  PubMed  Google Scholar 

  • Di Giovanni S, Valentini G, Carducci P, Giallonardo P (1989) Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 81:181

    PubMed  Google Scholar 

  • Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Tavade P, for the French Cooperative Groop on Chronic Lymphocytic Leukemia (1998) Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 21:1506

    Google Scholar 

  • Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580–1589

    PubMed  Google Scholar 

  • Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916

    PubMed  Google Scholar 

  • Dreger P, Montserrat E (2002) Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 16:985–992

    Article  PubMed  CAS  Google Scholar 

  • Dreger P, Stilgenbauer S, Benner A, Ritgen M, Kroeber A, Kneba M, Schmitz N Doehner H (2004) The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103:2850–2858

    Article  PubMed  CAS  Google Scholar 

  • Eichhorst B, Busch R, Hopfinger G, Pasold R, Hensel M, Sölling U, Siehl S, Steinbrecher C, Jäger U, Bergmann M, Wendtner CM, Hiddemann W, Emmerich B, Hallek M (2003) Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL). Results of a phase III study (CLL4 protocol) of the German CLL Study Group (GCLLSG). Blood 102:Abstr 243

    Google Scholar 

  • El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452–3459

    PubMed  Google Scholar 

  • Geisler CH, Philip P, Egelund Christensen B, Hou-Jensen K, Tinggaard Peterson N, Myhre Jensen O, Thorling K, Andersen E, Birgens HS, Drivsholm A, Ellegaard J, Larsen JK, Plesner T, Brown P, Kragh Andersen P, Mørk Hansen M(1997) In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 21:1011–1023

    Article  PubMed  CAS  Google Scholar 

  • Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, Scielzo C, Caligaris-Cappio F (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101:1262–1269

    Article  PubMed  CAS  Google Scholar 

  • Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E, Emmerich B (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93:1732

    PubMed  CAS  Google Scholar 

  • Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848

    PubMed  CAS  Google Scholar 

  • Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023–1029

    Article  PubMed  CAS  Google Scholar 

  • Haslinger C, Schweifer N, Stilgenbauer S, Döhner H, Lichter P, Kraut N, Stratowa C Abseher R (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 22:3937–3949

    Article  PubMed  CAS  Google Scholar 

  • Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kröber A, Jäger U, Lichter P, Döhner H, Stilgenbauer S (2005) Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis associated genes. J Clin Oncol (Epub ahead of print)

    Google Scholar 

  • Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625–1638

    Article  PubMed  CAS  Google Scholar 

  • Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S (2002) VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410–1416

    PubMed  Google Scholar 

  • Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404–1409

    PubMed  CAS  Google Scholar 

  • Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Profitt JH, Lucas D, Grever MR, Byrd JC (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278–3281

    Article  PubMed  CAS  Google Scholar 

  • Maloum K, Magnac C, Cazin B, Divine M, Lepretre S, Delmer A, Leporrier M, Jaubert J, Dreyfus B, Guibon O, Dighiero G, Merle-Beral H (2003) Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia predictive value of mutational IgVH gene status for incomplete response and relapse after oral fludarabine phosphate (Fludara oral) and cyclophosphamide in previously untreated CLL patients. Blood 102:Abstr 110

    Google Scholar 

  • Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD, McConkey C, Child JA, Cunningham D, Morgan GJ, Catovsky D; National Cancer Research Institute Haematological Studies Group (2005) Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105:397–404

    Article  PubMed  CAS  Google Scholar 

  • Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedu J, Bosch F, Lopez-Guillermo A, Campo E, Sierra J, Montserrat E (2005) Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Oncol (Epub ahead of print)

    Google Scholar 

  • Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62:567

    PubMed  CAS  Google Scholar 

  • Orchard J, Davis Z, Ibbotson R, Richards S, Catovsky D, Oscier D (2003) Comparison of ZAP-70, IgVHgene mutational status and CD38 in CLL patients requiring therapy: preliminary report from the UK CLL IV Trial. Blood 102:Abstr 105

    Google Scholar 

  • Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177–1184

    PubMed  CAS  Google Scholar 

  • Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Paternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219

    PubMed  CAS  Google Scholar 

  • Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H, Stuhr A, Kneba M, Dreger P (2003) Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101:2049–2053

    Article  PubMed  CAS  Google Scholar 

  • Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C, Raff T, Kröber A, Bunjes D, Schlenk R, Schmitz N, Döhner H, Kneba M, Dreger P (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600–2602

    Article  PubMed  CAS  Google Scholar 

  • Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639–1647

    Article  PubMed  CAS  Google Scholar 

  • Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R, Rios A, Prados D, Morey M, Gomis F, Alcala A, Gutierrez M, Maldonado J, Gonzales C, Giralt M, Hernandez-Nieto L, Cabrera A, Fernandez-Ranada JM (1984) Bone marrow histologic pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 64:642

    PubMed  CAS  Google Scholar 

  • Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, Kestler HA, Haslinger C, Stilgenbauer S, Dohner H, Bentz M, Lichter P (2004) Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 101:1039–1044

    Article  PubMed  CAS  Google Scholar 

  • Stilgenbauer S, Döhner H (2002b) Campath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347:452–453 (letter)

    Article  PubMed  Google Scholar 

  • Stilgenbauer S, Kröber A, Winkler D, Kienle D, Busch R, Emmerich B, Hallek M, Döhner H, for the GCLLSG (2002a) VH mutation status and genomic aberrations in the prospective CLL1 trial (Binet-A) of the German CLL Study Group (GCLLSG). Blood 100:168a (Abstr 628)

    Google Scholar 

  • Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG (2005) Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol (Epub ahead of print)

    Google Scholar 

  • Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, Botling J, Enblad G, Sallstrom J, Sundstrom C, Roos G, Rosenquist R (2002) Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99:2262–2264

    Article  PubMed  CAS  Google Scholar 

  • Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, Yamamoto M, Pritsch O, Merle-Beral H, Maloum K, Ajchenbaum-Cymbalista F, Dighiero G (2003) Binet’s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 21:3928–3932

    Article  PubMed  CAS  Google Scholar 

  • Zwiebel JA, Cheson BD (1998) Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 25:42

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University of Ulm, Robert-Koch-Str. 8, Ulm, Germany

    S. Stilgenbauer & H. Döhner

Authors
  1. S. Stilgenbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Döhner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stilgenbauer, S., Döhner, H. (2005). Genotypic Prognostic Markers. In: Chronic Lymphocytic Leukemia. Current Topics in Microbiology and Immunology, vol 294. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29933-5_9

Download citation

Publish with us

Policies and ethics

Search

Navigation